PATENT CLAIM ANALYSIS

Application Number: 15873099
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "001100"]

Abstract:
The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.

Claim (Index 7):
The method of  claim 6 , wherein increased LV function is determined by one or more physiological measures factors from the group consisting of reduced LV stroke volume, improved LV ejection fraction, improved fractional shortening, reduced infarct expansion, improved hemodynamics, and reduced lung volumes.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.57447
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14899007', '14771408', '14347998', '14418827', '14418809']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7869444960982716
- 35 USC 102 Novelty (BERT): 0.5235322760722868
- Combined Prediction Score: 0.7606032740956731
- Mean Citation Score: 253.04150600000003
- Max Citation Score: 334.4941
- Similarity Product: 267.9179708390117

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test